What is Theriva Biologics's market cap?

Theriva Biologics (TOVX) has a market capitalization of $9.8M and trades on AMEX.

Who are Theriva Biologics's competitors?

Theriva Biologics's key competitors include Seres Therapeutics, Inc., Amgen Inc., Candel Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Theriva Biologics partner with?

Theriva Biologics's notable partners include Rasayana Therapeutics, Inc..

What subsidiaries does Theriva Biologics have?

Theriva Biologics's subsidiaries include Theriva Biologics, S.L. (VCN).

Where is Theriva Biologics headquartered?

Theriva Biologics is headquartered in United States of America and employs approximately 22 people. It has been publicly traded since 1993.

Theriva Biologics

TOVX

Theriva Biologics is a clinical-stage biotechnology company focused on developing next-generation therapeutics for cancer and gastrointestinal diseases.

Market cap

$9.78M+153%

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$300.0KIn line EPS-$0.05In line

Read the full report

Next report

Aug 12, 2026 (In 2 weeks)

Revenue estimate$300.0K

EPS estimate-$0.06

Competitors

By market cap

Amgen$203.07B+25.3%

Immunome$2.6B+171%

Candel Therapeutics, Inc.$729.8M+112%

Replimune Group$724.4M+194%

Relmada Therapeutics, Inc.$545.9M+2,468%

Seres Therapeutics$47.0M-59.4%

Theriva Biologics$9.8M+124%

Calidi Biotherapeutics$2.1M-88.9%

By revenue growth

Amgen+9.1%

Immunome-63.3%

By net margin

Amgen20.96%+3.6pp

Immunome-5,593.85%-3,719pp

Candel Therapeutics, Inc.-15,156.45%—

Profile

Theriva Biologics is a clinical-stage biotechnology company focused on developing next-generation therapeutics for cancer and gastrointestinal diseases. The company leverages a proprietary oncolytic adenovirus platform designed for intravenous and intravitreal delivery to trigger tumor cell death and enhance the efficacy of co-administered therapies.

Competitive position

Theriva is transitioning from a GI-focused firm to an oncology-specialized developer using a unique adenovirus platform to address solid tumors.

GeographiesUnited States, Spain, Global

Customer segmentsHealthcare providers, Biopharmaceutical companies

Business modelR&D, Licensing, Clinical-stage development

SupplierscGMP manufacturing facilities, Clinical trial investigators, Genetic engineering technology

CustomersPharmaceutical companies, Specialty clinics, Research hospitals

CountryUnited States of America

Listed1993

Employees22.0

CEOSteven A. Shallcross

SectorHealthcare

IndustryBiotechnology

Websitetherivabio.com

FilingsSEC EDGAR

Questions, answered.

What is Theriva Biologics's market cap?: Theriva Biologics (TOVX) has a market capitalization of $9.8M and trades on AMEX.
Who are Theriva Biologics's competitors?: Theriva Biologics's key competitors include Seres Therapeutics, Inc., Amgen Inc., Candel Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Theriva Biologics partner with?: Theriva Biologics's notable partners include Rasayana Therapeutics, Inc..
What subsidiaries does Theriva Biologics have?: Theriva Biologics's subsidiaries include Theriva Biologics, S.L. (VCN).
Where is Theriva Biologics headquartered?: Theriva Biologics is headquartered in United States of America and employs approximately 22 people. It has been publicly traded since 1993.